scholarly journals Prediction of corneal graft rejection using central endothelium/Descemet’s membrane complex thickness in high-risk corneal transplants

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Taher Eleiwa ◽  
Amr Elsawy ◽  
Eyup Ozcan ◽  
Collin Chase ◽  
William Feuer ◽  
...  

AbstractTo determine whether measurements of Endothelium/Descemet complex thickness (En/DMT) are of predictive value for corneal graft rejection after high-risk corneal transplantation, we conducted this prospective, single-center, observational case series including sixty eyes (60 patients) at high risk for corneal graft rejection (GR) because of previous immunologic graft failure or having at least two quadrants of stromal vascularization. Patients underwent corneal transplant. At 1st, 3rd, 6th, 9th, and 12th postoperative month, HD-OCT imaging of the cornea was performed, and the corneal status was determined clinically at each visit by a masked cornea specialist. Custom-built segmentation tomography algorithm was used to measure the central En/DMT. Relationships between baseline factors and En/DMT were explored. Time dependent covariate Cox survival regression was used to assess the effect of post-operative En/DMT changes during follow up. A longitudinal repeated measures model was used to assess the relationship between En/DMT and graft status. Outcome measures included graft rejection, central Endothelium/Descemet’s complex thickness, and central corneal thickness (CCT). In patients with GR (35%), the central En/DMT increased significantly 5.3 months (95% CI: 2, 11) prior to the clinical diagnosis of GR, while it remained stable in patients without GR. During the 1-year follow up, the rejected grafts have higher mean pre-rejection En/DMTs (p = 0.01), compared to CCTs (p = 0.7). For En/DMT ≥ 18 µm cut-off (at any pre-rejection visit), the Cox proportional hazard ratio was 6.89 (95% CI: 2.03, 23.4; p = 0.002), and it increased to 9.91 (95% CI: 3.32, 29.6; p < 0.001) with a ≥ 19 µm cut-off. In high-risk corneal transplants, the increase in En/DMT allowed predicting rejection prior to the clinical diagnosis.

2021 ◽  
pp. 112067212110640
Author(s):  
Miltiadis Balidis ◽  
Dimitrios Mikropoulos ◽  
Zisis Gatzioufas ◽  
Penelope B de Politis ◽  
Georgios Sidiropoulos ◽  
...  

Purpose This study intends to add to previous reports on acute corneal graft rejection following anti-severe acute respiratory syndrome-coronavirus-2 vaccination, providing data to corroborate a possible causative relationship between anti-COVID-19 immunization and corneal graft rejection, regardless of vaccine or graft type. Methods and Results This report describes 4 cases of acute-onset rejection as early as 5 days following the first dose of anti-severe acute respiratory syndrome-coronavirus-2 vaccine types not yet referred for corneal allograft. Patients were individually given the Moderna messenger RNA-1273 COVID-19 vaccine (2 patients) and the AstraZeneca COVID-19 vaccine, Vaxzevria, AZD1222 (2 patients). Conclusions Even though a direct causative effect is hard to prove, temporal proximity between anti-severe acute respiratory syndrome-coronavirus-2 vaccines of different types and consecutive reports of corneal graft rejection indicates the need for further investigation. Consistent advice must be given to corneal transplant patients regarding such risk.


2015 ◽  
Vol 253 (10) ◽  
pp. 1765-1776 ◽  
Author(s):  
Qin Qin ◽  
Yunjie Shi ◽  
Qingqing Zhao ◽  
Dan Luo ◽  
Yuan Chen ◽  
...  

2016 ◽  
Vol 57 (4) ◽  
pp. 1578 ◽  
Author(s):  
Lucia Kuffova ◽  
Jared E. Knickelbein ◽  
Tian Yu ◽  
Carlos Medina ◽  
Guillermo Amescua ◽  
...  

2019 ◽  
Vol 5 (5) ◽  
pp. e452 ◽  
Author(s):  
Deniz Hos ◽  
Viet Nhat Hung Le ◽  
Martin Hellmich ◽  
Sebastian Siebelmann ◽  
Sigrid Roters ◽  
...  

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1274
Author(s):  
Matteo Nioi ◽  
Ernesto d’Aloja ◽  
Maurizio Fossarello ◽  
Pietro Emanuele Napoli

Present mass vaccination against Coronavirus Disease-19 (COVID-19) is the most widely used health policy and the most promising approach to curb the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic globally. However, new side effects are emerging from the mass vaccination not described during the experimental stages. In the present study, we discuss a case of acute corneal graft rejection, which has occurred 25 years after transplantation and 13 days after the administration of the BNT162b2 vaccine (Comirnaty, BioNTech/Pfizer), which was followed-up for a period of six months. In this period, the corneal inflammation appeared twice but was successfully managed with topical therapy and supplementation of Vitamin D. A risk of corneal graft rejection must be included in the list of potential vaccine complications, in order to inform the transplanted patient to undergo a preliminary and a follow-up ocular examination, and eventually to include corneal graft in the list of contraindications to vaccination.


Sign in / Sign up

Export Citation Format

Share Document